Peter Hoang

Directeur/Membre du Conseil chez Esperance Pharmaceuticals, Inc.

Profil

Peter L.
Hoang currently works at Esperance Pharmaceuticals, Inc., as Director.
Mr. Hoang also formerly worked at Marker Therapeutics, Inc., as President, Chief Executive Officer & Director from 2017 to 2023, Tapimmune, Inc., as President & Chief Executive Officer, Oppenheimer & Co., Inc., as Executive Director-Global Mergers & Acquisitions, The University of Texas M.D.
Anderson Cancer Center, as Managing Director-Innovations from 2012 to 2014, CIT Group, Inc., as MD, Head-Healthcare Mergers & Acquisitions from 2010 to 2012, JPMorgan Chase & Co., as Head-Mergers & Acquisitions, Bellicum Pharmaceuticals, Inc., as Senior VP-Business Development & Strategy from 2014 to 2017, Deutsche Bank Corp., as Head-Mergers & Acquisitions, and Merrill Lynch & Co., Inc., as Head-Mergers & Acquisitions.
Mr. Hoang received his undergraduate degree from Yale University and Masters Business Admin degree from UCLA Anderson School of Management.

Postes actifs de Peter Hoang

Sociétés	Poste	Début
Esperance Pharmaceuticals, Inc.	Directeur/Membre du Conseil	-

Anciens postes connus de Peter Hoang

Sociétés	Poste	Fin
MARKER THERAPEUTICS, INC.	Directeur Général	01/05/2023
BELLICUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/03/2017
The University of Texas M.D. Anderson Cancer Center	Corporate Officer/Principal	01/11/2014
CIT GROUP INC.	Corporate Officer/Principal	01/03/2012
Tapimmune, Inc.	Directeur Général	-